Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4A1 | P60842 | 19/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12455880 | 0.89 | EIF4A1 (0.76) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| SCHEMBL15077722 | 0.89 | EIF4A1 (0.76) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| SCHEMBL12455875 | 0.89 | EIF4A1 (0.76) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| SCHEMBL2616376 | 0.89 | EIF4A1 (0.51) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| SCHEMBL2616375 | 0.88 | EIF4A1 (0.52) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| SCHEMBL2616370 | 0.87 | EIF4A1 (0.65) | EIF4A1CYP3A4HIF1A | |
| SCHEMBL2616368 | 0.86 | EIF4A1 (0.54) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| SCHEMBL18877894 | 0.84 | EIF4A1 (0.52) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| SCHEMBL18470692 | 0.82 | EIF4A1 (0.66) | EIF4A1NFKB1RELACYP3A4HIF1A | |
| SCHEMBL18864412 | 0.81 | EIF4A1 (0.63) | EIF4A1NFKB1RELACYP3A4HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101153-A1 | ROCAGLAOL DERIVATIVES AS CARDIOPROTECTANT AGENTS AND AS ANTINEOPLASTIC AGENTS | UNIVERSITE DE STRASBOURG (FR) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101153-A1 | ROCAGLAOL DERIVATIVES AS CARDIOPROTECTANT AGENTS AND AS ANTINEOPLASTIC AGENTS | BAX, BAD, CASP3 | EIF4A1 4136/4885NFKB1 2164/4885RELA 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.